Publications by authors named "Helga Bernhard"

Claim this Profile
P
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.
Tim Richardson, Elias Mai, Ekaterina Menis, Axel Benner, Diana Tichy, Helga Bernhard

Eur J Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
Patrick Derigs, Maria-Luisa Schubert, Peter Dreger, Anita Schmitt, Schayan Yousefian, Helga Bernhard

Leukemia· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial.
Ulrich Dührsen, Andreas Bockisch, Bernd Hertenstein, Imke E Karsten, Frank Kroschinsky, Helga Bernhard

Blood Neoplasia· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
Natalie Berghaus, Sarah Schreiner, Alexandra M Poos, Marc S Raab, Hartmut Goldschmidt, Helga Bernhard

FEBS J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
Markus Moehler, Gunnar Folprecht, Volker Heinemann, Julian Walter Holch, Annett Maderer, Bernhard Linz, Helga Bernhard

Int J Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
Elias K Mai, Kaya Miah, Uta Bertsch, Jan Dürig, Christof Scheid, Helga Bernhard

Leukemia· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.
Eva-Maria Klein, Diana Tichy, Hans J Salwender, Elias K Mai, Jan Duerig, Helga Bernhard

Cancers (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
Elias K Mai, Kaya Miah, Uta Bertsch, Jan Dürig, Christof Scheid, Helga Bernhard

Leukemia· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Marc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, Uta Bertsch, Hans J Salwender, Helga Bernhard

Blood Cancer J· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Christine Schmitz, Jan Rekowski, Stefan P Müller, Bernd Hertenstein, Christiane Franzius, Helga Bernhard

Hematol Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).
Carl Christoph Schimanski, Stefan Kasper, Susanna Hegewisch-Becker, Jan Schröder, Friedrich Overkamp, Helga Bernhard

Oncoimmunology· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
Hartmut Goldschmidt, Elias K Mai, Jan Dürig, Christof Scheid, Katja C Weisel, Bernhard Rabold, Helga Bernhard

Leukemia· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.
Martin Sebastian, Andreas Schröder, Birgit Scheel, Henoch S Hong, Anke Muth, Helga Bernhard

Cancer Immunol Immunother· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Salah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, Thorsten O Goetze, Johannes Meiler, Helga Bernhard

Lancet· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Andreas Hüttmann, Jan Rekowski, Stefan P Müller, Bernd Hertenstein, Christiane Franzius, Helga Bernhard

Ann Hematol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
Ulrich Dührsen, Stefan Müller, Bernd Hertenstein, Henrike Thomssen, Jörg Kotzerke, Helga Bernhard

J Clin Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.
Christian Straka, Peter Liebisch, Hans Salwender, Burkhard Hennemann, Bernd Metzner, Helga Bernhard

Haematologica· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes.
Nisit Khandelwal, Marco Breinig, Tobias Speck, Tillmann Michels, Christiane Kreutzer, Helga Bernhard

EMBO Mol Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates.
Julia Karbach, Sacha Gnjatic, Melina Biskamp, Akin Atmaca, Eckhart Weidmann, Helga Bernhard

Cancer Immunol Res· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.
Sheena N Smith, Daniel Sommermeyer, Kurt H Piepenbrink, Sydney J Blevins, Helga Bernhard

J Mol Biol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.
Hans-Henning Schmidt, Yingzi Ge, Felix J Hartmann, Heinke Conrad, Felix Klug, Helga Bernhard

Oncoimmunology· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6.
Mathias Witzens-Harig, Dirk Hose, Simone Jünger, Christina Pfirschke, Nisit Khandelwal, Helga Bernhard

Blood· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.
Daniel Sommermeyer, Heinke Conrad, Holger Krönig, Haike Gelfort, Helga Bernhard

Int J Cancer· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficiency of human cytomegalovirus pp65(495-503) CD8+ T cell epitope generation is determined by the balanced activities of cytosolic and endoplasmic reticulum-resident peptidases.
Sabrina Urban, Kathrin Textoris-Taube, Barbara Reimann, Katharina Janek, Tanja Dannenberg, Helga Bernhard

J Immunol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease.
Holger Krönig, Kathrin Julia Falchner, Marcus Odendahl, Bettina Brackertz, Heinke Conrad, Bernhard Haller, Helga Bernhard

Int J Cancer· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis